Results 91 to 100 of about 5,604 (187)

Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat**not yet published**

, 2013
Obstructive sleep apnea represents a significant public health concern. Afferent vagal activation is implicated in increased apnea susceptibility by reducing upper airway muscle tone via activation of serotonin receptors in the nodose ganglia.
Miodrag Radulovacki (7945958), Michael W. Calik (7945955), David W. Carley (7923227)   +2 more
core   +1 more source

Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats

, 2018
Study Objectives: There are no pharmacological treatments for obstructive sleep apnea syndrome, but dronabinol showed promise in a small pilot study. In anesthetized rats, dronabinol attenuates reflex apnea via activation of cannabinoid (CB) receptors ...
DW Carley (7924103), MW Calik (7924100)
core  

Profils cinétiques du Δ

, 2009
Ce travail présente le volet pharmacocinétique d'une étude clinique plus large ayant comme objectif principal d'évaluer les effets d'une prise orale de cannabis ou de dronabinol (Marinol®) sur la capacité à conduire. Cette étude croisée a été réalisée en
Laura E. Rothuizen, Monique Appenzeller, Thierry Buclin, Marie A. Pin, Annick Menetrey, Patrice Mangin, Marc Augsburger, Bernard Favrat, Christian Giroud   +8 more
core   +1 more source

Neuropathic itch treated with oral cannabinoids: A case series

JAAD Case Reports, 2021
Catherine Besner Morin, MD, Haya S. Raef, MSc, Sarina B. Elmariah, MD, PhD   +2 more
doaj   +1 more source

Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat**not yet published**

, 2016
Obstructive sleep apnea represents a significant public health concern. Afferent vagal activation is implicated in increased apnea susceptibility by reducing upper airway muscle tone via activation of serotonin receptors in the nodose ganglia.
Miodrag Radulovacki (7945958), Michael W. Calik (7945955), David W. Carley (7923227)   +2 more
core  

Convergent Modifiers of Exposure Variability in Approved Cannabinoid Medicines: Pharmacogenomics, Drug-Drug Interactions, and Parent-Metabolite Divergence. [PDF]

Pharmaceutics
Bagher AM.
europepmc   +1 more source

Evaluation of dronabinol to decrease opioid use for cancer-induced bone pain. [PDF]

Oncologist
Segar J, Farr K, Junak M, Roe D, Ehsani S, Ibrahim M, Vanderah TW, Chalasani P.   +7 more
europepmc   +1 more source

Cannabinoids for pain management in rheumatoid arthritis: a scoping review of clinical evidence and mechanisms. [PDF]

Rheumatol Int
Zintziovas N, Karakosta A, Voulgari P, Stefanakis G, Arnaoutoglou E, Tzimas P, Micha G.   +6 more
europepmc   +1 more source

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone

Medical cannabis, nabiximols, dronabinol and nabilone are used for various medical conditions. Despite their pronounced pharmacokinetic variability and complex concentration–effect relationships, therapeutic drug monitoring recommendations are lacking ...
Hart, Xenia M., Havemann-Reinecke, Ursula, Amann, Friederike, Cremer-Schaeffer, Peter, Zernig, Gerald, Gründer, Gerhard, Häuser, Winfried, Hefner, Gudrun, Petzke, Frank   +8 more
core   +1 more source

Novel pharmacotherapies for opioid use disorder and opioid withdrawal. [PDF]

Front Psychiatry
Shen MR, Owusu-Boaitey K, Murphy ZD, Rains AN, Wang PR, Zhou DW, Suzuki J.   +6 more
europepmc   +1 more source